HRP20140102T1 - Cjepivo za prevenciju relapsa raka dojke - Google Patents

Cjepivo za prevenciju relapsa raka dojke Download PDF

Info

Publication number
HRP20140102T1
HRP20140102T1 HRP20140102AT HRP20140102T HRP20140102T1 HR P20140102 T1 HRP20140102 T1 HR P20140102T1 HR P20140102A T HRP20140102A T HR P20140102AT HR P20140102 T HRP20140102 T HR P20140102T HR P20140102 T1 HRP20140102 T1 HR P20140102T1
Authority
HR
Croatia
Prior art keywords
preparation
preparation according
formulated
human
injection
Prior art date
Application number
HRP20140102AT
Other languages
English (en)
Croatian (hr)
Inventor
George E. Peoples
Ponniah Sathibalan
Original Assignee
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. filed Critical The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
Publication of HRP20140102T1 publication Critical patent/HRP20140102T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/38—Antigens from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HRP20140102AT 2007-06-01 2008-04-11 Cjepivo za prevenciju relapsa raka dojke HRP20140102T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94152407P 2007-06-01 2007-06-01
PCT/US2008/060044 WO2008150577A1 (en) 2007-06-01 2008-04-11 Vaccine for the prevention of breast cancer relapse

Publications (1)

Publication Number Publication Date
HRP20140102T1 true HRP20140102T1 (hr) 2014-03-28

Family

ID=40094045

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140102AT HRP20140102T1 (hr) 2007-06-01 2008-04-11 Cjepivo za prevenciju relapsa raka dojke

Country Status (16)

Country Link
US (6) US8222214B2 (cg-RX-API-DMAC7.html)
EP (2) EP2162149B1 (cg-RX-API-DMAC7.html)
JP (6) JP5635399B2 (cg-RX-API-DMAC7.html)
KR (5) KR101863534B1 (cg-RX-API-DMAC7.html)
CN (2) CN105816867A (cg-RX-API-DMAC7.html)
AU (1) AU2008260399C1 (cg-RX-API-DMAC7.html)
CA (1) CA2687368C (cg-RX-API-DMAC7.html)
CY (1) CY1114912T1 (cg-RX-API-DMAC7.html)
DK (1) DK2162149T3 (cg-RX-API-DMAC7.html)
ES (1) ES2445399T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20140102T1 (cg-RX-API-DMAC7.html)
MX (1) MX2009012858A (cg-RX-API-DMAC7.html)
PL (1) PL2162149T3 (cg-RX-API-DMAC7.html)
PT (1) PT2162149E (cg-RX-API-DMAC7.html)
SI (1) SI2162149T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008150577A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
ES2445399T3 (es) * 2007-06-01 2014-03-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vacuna para la prevención de la recaida del cáncer de mama
CN105435218A (zh) 2008-12-10 2016-03-30 亨利·M·杰克逊军事医学促进基金会 预防乳腺癌复发的疫苗
JP6170076B2 (ja) 2012-02-17 2017-07-26 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ ＨＥＲ２／ｎｅｕポリペプチドを発現する癌細胞を認識する能力を有するＣＤ８＋Ｔ細胞を作製するための方法および材料
WO2013169538A1 (en) 2012-05-08 2013-11-14 Albert Einstein College Of Medicine Of Yeshiva University Nanoparticle delivery vehicle for s-nitroso-n-acetyl cysteine and uses thereof
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
EP2762161A1 (en) * 2013-02-05 2014-08-06 Nitto Denko Corporation E75-vaccine composition for mucosal administration
EP2762158A1 (en) * 2013-02-05 2014-08-06 Nitto Denko Corporation E75-vaccine composition for transdermal administration
EP2777711A1 (en) 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
CN104513293A (zh) * 2013-09-26 2015-04-15 深圳信立泰药业股份有限公司 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品
WO2015066020A1 (en) * 2013-10-28 2015-05-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of monitoring immune responses
US10434152B2 (en) * 2014-02-20 2019-10-08 Wayne State University HER2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas
BR112018015480A2 (pt) 2016-01-29 2019-05-21 Sorrento Therapeutics, Inc. proteínas de ligação ao antígeno que se ligam a pd-l1
MA45169A (fr) 2016-05-31 2019-04-10 Sellas Life Sciences Group Inc Thérapie vaccinale pour le traitement du cancer de l'endomètre et de l'ovaire
JP2022512038A (ja) 2018-10-21 2022-02-01 エスエルエスジー リミテッド エルエルシー トリプルネガティブ乳癌治療のための併用免疫療法
JP2024515574A (ja) 2021-05-04 2024-04-10 アストン エスシーアイ． インコーポレイテッド Ｈｅｒ２ワクチン組成物
KR20230017640A (ko) 2021-07-28 2023-02-06 주식회사 애스톤사이언스 Her2 백신 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
EP0474727B1 (en) * 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
AU712441B2 (en) * 1994-12-14 1999-11-04 Scripps Research Institute, The In vivo activation of tumor-specific cytotoxic T cells
US6514942B1 (en) 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US20030022820A1 (en) * 1995-12-14 2003-01-30 Linda A. Sherman In vivo activation of tumor-specific cytotoxic t cells
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
AU6620300A (en) * 1999-08-03 2001-02-19 Ohio State University, The Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
WO2001023421A2 (en) 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US20030224036A1 (en) * 1999-12-13 2003-12-04 Fikes John D Hla class I a2 tumor associated antigen peptides and vaccine compositions
US20070098776A1 (en) * 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
WO2003004609A2 (en) * 2001-07-03 2003-01-16 Lexicon Genetics Incorporated Novel human kielin-like proteins and polynucleotides encoding the same
NZ530315A (en) * 2001-07-10 2007-01-26 Corixa Corp Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
US8802618B2 (en) 2002-03-08 2014-08-12 Board Of Regents, The University Of Texas System Controlled modulation of amino acid side chain length of peptide antigens
KR100555211B1 (ko) * 2002-07-16 2006-03-03 주식회사 팬제노믹스 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신
WO2004030636A2 (en) * 2002-10-03 2004-04-15 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
WO2004069866A1 (en) * 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
WO2005046571A2 (en) * 2003-06-06 2005-05-26 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005014634A1 (en) * 2003-08-12 2005-02-17 Agt Biosciences Limited A gene and uses therefor
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
US20060275777A1 (en) * 2005-06-03 2006-12-07 Waelti Ernst R Novel strategies for protein vaccines
ES2445399T3 (es) * 2007-06-01 2014-03-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vacuna para la prevención de la recaida del cáncer de mama

Also Published As

Publication number Publication date
AU2008260399C1 (en) 2014-07-17
EP2722336A1 (en) 2014-04-23
CA2687368C (en) 2018-10-30
WO2008150577A1 (en) 2008-12-11
US20220241389A1 (en) 2022-08-04
CN101678093A (zh) 2010-03-24
AU2008260399B2 (en) 2014-01-16
EP2162149B1 (en) 2013-11-06
JP2014237653A (ja) 2014-12-18
US20190060429A1 (en) 2019-02-28
JP7072467B2 (ja) 2022-05-20
KR102079921B1 (ko) 2020-02-21
SI2162149T1 (sl) 2014-04-30
JP2022095926A (ja) 2022-06-28
KR102283639B1 (ko) 2021-08-02
KR20100027187A (ko) 2010-03-10
US20100209443A1 (en) 2010-08-19
US9370560B2 (en) 2016-06-21
DK2162149T3 (da) 2014-02-10
CA2687368A1 (en) 2008-12-11
JP6097724B2 (ja) 2017-03-15
KR20200019776A (ko) 2020-02-24
US20150182609A1 (en) 2015-07-02
AU2008260399A1 (en) 2008-12-11
JP2021001218A (ja) 2021-01-07
JP5635399B2 (ja) 2014-12-03
EP2162149A4 (en) 2012-07-25
KR101863534B1 (ko) 2018-06-04
EP2162149A1 (en) 2010-03-17
US10842856B2 (en) 2020-11-24
AU2008260399A8 (en) 2010-01-07
ES2445399T3 (es) 2014-03-03
KR20150106870A (ko) 2015-09-22
MX2009012858A (es) 2010-02-03
US8796220B2 (en) 2014-08-05
US8222214B2 (en) 2012-07-17
KR20180061412A (ko) 2018-06-07
US20220347281A1 (en) 2022-11-03
PL2162149T3 (pl) 2014-04-30
JP2017071607A (ja) 2017-04-13
KR101572474B1 (ko) 2015-11-30
US20130189290A1 (en) 2013-07-25
KR20210097209A (ko) 2021-08-06
PT2162149E (pt) 2014-02-12
JP2010529026A (ja) 2010-08-26
CN105816867A (zh) 2016-08-03
JP2018199691A (ja) 2018-12-20
CY1114912T1 (el) 2017-01-25

Similar Documents

Publication Publication Date Title
HRP20140102T1 (hr) Cjepivo za prevenciju relapsa raka dojke
JP2010529026A5 (cg-RX-API-DMAC7.html)
RU2435782C2 (ru) Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция
Donohue et al. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
ES2441724T3 (es) Composiciones de lectina y procedimientos para modular una respuesta inmunitaria a un antígeno
CN1629185A (zh) 结核杆菌抗原融合蛋白及其应用
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
JPH07504683A (ja) Ｇｍ−ｃｓｆのワクチンアジュバントとしての利用
JP2005526085A5 (cg-RX-API-DMAC7.html)
AU2025202861A1 (en) Vaccine compositions and methods for restoring NKG2D pathway function against cancers
CN104338132A (zh) 一种病毒免疫治疗药物复合物及其用途
RU2015106742A (ru) Композиции, содержащие химерные молекулы ospa и способы их применения
del Carmen Domínguez et al. Biodistribution and pharmacokinetic profiles of an altered peptide ligand derived from heat-shock proteins 60 in Lewis rats
Du et al. HBV DNA vaccine with adjuvant cytokines induced specific immune responses against HBV infection
ES2647584T3 (es) Método para producir vacunas que comprende la irradiación de microorganismos en una composición que comprende aminoácidos y ortofosfato de manganeso
Bellanti BIOLOGIC SIGNIFICANCE OF THE SECRETORY γA IMMUNOGLOBULINS: E. Mead Johnson Award Address
Kim et al. Dectin-1 signaling coordinates innate and adaptive immunity for potent host defense against viral infection
CN109200270B (zh) 一种能提高多肽疫苗对hpv感染肿瘤治疗效果的联合用药物及其应用
FI3733712T3 (fi) Hoito-ohjelmia ja menetelmiä pesäkekovettumataudin hoitamiseksi ofatumumabia käyttämällä
Zhang et al. Modulation by glycyrrhizin of the cell-surface expression of H-2 class I antigens on murine tumour cell lines and normal cell populations
RU2014109137A (ru) Пептиды mphosph1 и вакцины, включающие их
JP2013506682A5 (cg-RX-API-DMAC7.html)
CN101838306A (zh) 一种k4多肽合成产物及其应用
CN104096229B (zh) 甘氨酸锌佐剂及含甘氨酸锌佐剂的疫苗
Feng et al. Isolation and potential immunological characterization of TPSGLVY, a novel bursal septpeptide isolated from the bursa of Fabricius